Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration

International Journal of Antimicrobial Agents

Volumn 42, Issue 3, 2013, Pages 244-249

  Zhang, Li ^a,b   Li, Li ^a,c   Shi, Wei ^a   Liu, Shuangxin ^a   Liang, Xinling ^a   Ye, Zhiming ^a   Wang, Wen Jiang ^a   Zhang, Bin ^a   Li, Ruizhao ^a   Chen, Yuanhan ^a   Yu, Chunping ^a   Zhuo, Li ^a   Wang, Xipei ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c YUEBEI PEOPLE S HOSPITAL   (China)

Author keywords

Critically ill patients; Moxifloxacin; Pharmacodynamics; Pharmacokinetics; Pulse high volume haemofiltration

Indexed keywords

MOXIFLOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

CRITICALLY ILL PATIENTS; MOXIFLOXACIN; PHARMACODYNAMICS; PHARMACOKINETICS; PULSE HIGH-VOLUME HAEMOFILTRATION;

AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEMOFILTRATION; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLINES; RENAL INSUFFICIENCY;

EID: 84883450027     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.06.007     Document Type: Article

References (31)

1. M. Souli, C.B. Wennersten, and G.M. Eliopoulos In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens Int J Antimicrob Agents 10 1998 23 30
2. A.P. MacGowan Moxifloxacin (BAY 12-8039): a new methoxy quinolone antibacterial Expert Opin Investig Drugs 8 1999 181 199
3. G.G. Zhanel, K. Ennis, L. Vercaigne, A. Walkty, A.S. Gin, and J. Embil A critical review of the fluoroquinolones: focus on respiratory infections Drugs 62 2002 13 59
4. C. Ballow, J. Lettieri, V. Agarwal, P. Liu, H. Stass, and J.T. Sullivan Absolute bioavailability of moxifloxacin Clin Ther 21 1999 513 522
5. H. Stass, and D. Kubitza Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man J Antimicrob Chemother 43 Suppl. B 1999 83 90
6. H. Stass, D. Kubitza, A. Halabi, and H. Delesen Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction Br J Clin Pharmacol 53 2002 232 237
7. P.A. Moise, M.C. Birmingham, and J.J. Schentag Pharmacokinetics and metabolism of moxifloxacin Drugs Today (Barc) 36 2002 229 244
8. J.T. Sullivan, J.T. Lettieri, P. Liu, and A.H. Heller The influence of age and gender on the pharmacokinetics of moxifloxacin Clin Pharmacokinet 40 2001 11 18
9. C. Tetta, R. Bellomo, J. Kellum, Z. Ricci, R. Pohlmeiere, and J. Passlick-Deetjen High volume hemofiltration in critically ill patients: why, when and how? Contrib Nephrol 144 2004 362 375
10. O. Joannes-Boyau, S. Rapaport, R. Bazin, C. Fleureau, and G. Janvier Impact of high volume hemofiltration on hemodynamic disturbance and outcome during septic shock ASAIO J 50 2004 102 109
11. A. Brendolan, V. D'Intini, Z. Ricci, M. Bonello, R. Ratanarat, and G. Salvatori Pulse high volume hemofiltration Int J Artif Organs 27 2004 398 403
12. R. Ratanarat, A. Brendolan, P. Piccinni, M. Dan, G. Salvatori, and Z. Ricci Pulse high-volume hemofiltration in critically ill patients: a new approach for patients with septic shock Semin Dial 19 2006 69 74
13. R. Ratanarat, A. Brendolan, P. Piccinni, M. Dan, G. Salvatori, and Z. Ricci Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival Crit Care 9 2005 R294 R302
14. H.M. Oudemans-van Straaten, R.J. Bosman, J.I. van der Spoel, and D.F. Zandstra Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis Intensive Care Med 25 1999 814 821
15. P.M. Honore, J. Jamez, M. Wauthier, P.A. Lee, T. Dugernier, and B. Pirenne Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock Crit Care Med 28 2000 3581 3587
16. S. Cotterill Antimicrobial prescribing in patients on haemofiltration J Antimicrob Chemother 36 1995 773 780
17. T.A. Golper, and M.A. Marx Drug dosing adjustments during continuous renal replacement therapies Kidney Int Suppl 66 1998 S165 S168
18. H.H. Stass, S. Dammer, D. Kubitza, J. Moeller, H. Delesen, and R. Schaefers No dose adjustment is needed for patients undergoing hemodialysis (HD) receiving oral moxifloxacin 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 27-30 September, San Diego, CA 2002 ASM Press Washington, DC [Abstract A-1383]
19. D. Czock, C. Hüsig-Linde, A. Langhoff, T. Schöpke, C. Hafer, and K. de Groot Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis Clin J Am Soc Nephrol 1 2006 1263 1268
20. V. Fuhrmann, P. Schenk, W. Jaeger, S. Ahmed, and F. Thalhammer Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration J Antimicrob Chemother 54 2004 780 784
21. M.H. Kollef Optimizing antibiotic therapy in the intensive care unit setting Crit Care 5 2001 189 195
22. F. Scaglione, and L. Paraboni Pharmacokinetics/pharmacodynamics of antibacterials in the intensive care unit: setting appropriate dosing regimens Int J Antimicrob Agents 32 2008 294 301
23. G.R. Matzke, G.R. Aronoff, A.J. Atkinson Jr., W.M. Bennett, B.S. Decker, and K.U. Eckardt Drug dosing consideration in patients with acute and chronic kidney disease - a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 80 2011 1122 1137
24. L. Shargel, S. Wu-pong, and A. Yu 6th ed. Applied biopharmaceutics and pharmacokinetics 2012 McGraw-Hill Companies Inc. New York, NY pp. 68, 114
25. J.M. Hyatt, P.S. McKinnon, G.S. Zimmer, and J.J. Schentag The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents Clin Pharmacokinet 28 1995 143 160
26. J. Turnidge Pharmacokinetics and pharmacodynamics of fluoroquinolones Drugs 58 1999 29 36
27. A.K. Hemanth Kumar, and G. Ramachandran Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma J Chromatogr B: Analyt Technol Biomed Life Sci 877 2009 1205 1208
28. S. Schulte, T. Ackermann, N. Bertram, T. Sauerbruch, and W.D. Paar Determination of the newer quinolones levofloxacin and moxifloxacin in plasma by high-performance liquid chromatography with fluorescence detection J Chromatogr Sci 44 2006 205 208
29. H. Stass, and A. Dalhoff Determination of BAY 12-8039, a new 8-methoxy-quinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing J Chromatogr B: Biomed Sci Appl 702 1997 163 174
30. A. Lubasch, I. Keller, K. Corner, P. Koeppe, and H. Lode Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers Antimicrob Agents Chemother 44 2000 2600 2603
31. G.M. Keating, and L.J. Scott Moxifloxacin: a review of its use in the management of bacterial infections Drugs 64 2004 2347 2377